Sage Tap Poder is proud to partner with Akston Biosciences, a cutting-edge biotechnology company at the forefront of innovation. Akston specializes in the development of transformative therapies, leveraging advanced protein engineering to create impactful solutions across multiple therapeutic areas.
đź’Ľ Explore Current Investment Opportunities
STPCM actively partners with innovative companies that meet their four key investment criteria:
🤝 Connect with STPCM
Whether you’re an entrepreneur seeking investment or an investor interested in partnering, STPCM welcomes inquiries. You can reach out through their contact page or email them directly at
Â
If you’re interested in exploring active investment opportunities with STPCM, here are two ventures currently open for participation:
Â
Koning Health is revolutionizing breast imaging with its Vera™ Breast CT system, offering:
True 3D Imaging: Provides detailed images, detecting smaller cancers often missed by traditional mammograms.
No Compression: Enhances patient comfort by eliminating the need for breast compression during scans.
Rapid Scans: Delivers 3D breast imaging in as little as 7 seconds.
With FDA, CE, and China approvals, and a global market potential exceeding $40 billion, Koning Health is seeking to raise $5 million to scale its operations globally.
Learn more: Koning Health
Â
MissMedical Ventures has developed a patented fetal scalp sensor array that measures fetal oxygen saturation (SpOâ‚‚) in real-time, addressing critical issues in labor and delivery:
Enhanced Accuracy: Reduces false positives in fetal distress detection, potentially decreasing unnecessary emergency C-sections.
Improved Outcomes: Provides vital oxygen data, aiding in timely and accurate clinical decisions during labor.
This innovation targets a significant gap in obstetric care, aiming to improve maternal and fetal health outcomes.
Learn more: Miss Medical Ventures
Â
Both opportunities align with STPCM’s focus on investing in ventures that address substantial market needs with de-risked technologies and clear exit strategies. If you have further questions or need assistance connecting with these ventures, feel free to ask!
Learn More About STPCM’s Approach
STPCM employs a process-driven approach to investing, emphasizing:stpcm.com
Their focus areas include early-stage ventures with innovative strategies, scalable growth solutions, and SPV investments.
Akston’s proprietary technology platform enables the creation of highly stable, long-acting protein therapeutics, addressing critical unmet needs in healthcare.
With a robust pipeline targeting immunology, infectious diseases, and oncology, Akston is positioned to deliver groundbreaking treatments to market.
Akston is led by a team of experienced scientists and industry veterans, driving the company toward scalable growth and long-term success.
Akston’s platform provides unique advantages in therapeutic stability, manufacturability, and efficacy.
Addressing multibillion-dollar markets with high growth potential, Akston offers significant value creation opportunities for stakeholders.
A team with a proven track record of innovation, execution, and strategic partnerships in the biotech sector.